CMP as on 07-Oct-22 14:58₹ 1,996.05
Turnover (lac)₹ 2,035
Prev. Close₹ 1,976.05
Day's Vol (shares)₹ 1,01,969
Day's Range (₹)
CMP as on07-Oct-22 14:57₹ 1,995.00
Turnover (lac)₹ 14
Prev. Close₹ 1,977.60
Day's Vol (shares)₹ 6,330
In a recent report, analysts at IIFL Securities highlight the export data trends for the month of July 2022. The month has been robust
High raw-material inflation, elevated freight expenses, and normalization in costs have impacted margins of Indian pharma players. Duri
In this report, analysts at IIFL Securities highlight prescription volumes and market share trends for the key US products for Indian g
PAT drops 45.5% yoy at Rs84 crore in Q3FY22 attributed to one-off income due to trademark sale in Q3FY21, higher treasury income in Q3F
The companys board had given approval for the acquisition of a portfolio of brands, for use and commercialization within India, from SP
The transaction is valued at Rs628cr and is expected to be completed in the next two weeks subject to customary closing formalities.
Recently Molnupiravir, received U.S. FDA, Emergency Use Authorization(EUA) for the Treatment of Mild to Moderate COVID-19.
The company records revenue growth of 34% yoy to Rs593cr in Q2FY22.
EBITDA margin for the quarter was at 27% as compared to 29.8%.
Midcap stocks were among the top outperformers with stocks like JB Chemicals, Care Rating & CCL Products closing with strong gains
Per Order for ETF & Mutual Funds Brokerage
Per Order for Delivery, Intraday, F&O, Currency & Commodity